COMP <GO>
APUS vs IMNN // EV/EBITDA & P/E VALUATION
Apimeds Pharmaceuticals US Inc. (NYSE) VS. Imunon Inc. (NASDAQ) • 15-METRIC TALLY: APUS 3
— IMNN 1
■ METRIC PARITY
LAST: $3.21 (+4.56%) • MKT CAP: $5.0M
valuation
—
LAST: $0.83 (+0.35%) • MKT CAP: $4.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APUS VS. IMNN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APUS | IMNN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.20% | -35.00% | +28.80 | APUS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | IMNN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.4 | 35.9 | +6.51 | APUS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.0M | $4.7M | $277.5K | APUS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APUS REV | IMNN REV | APUS GROSS % | IMNN GROSS % | APUS FCF | IMNN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$9.0M | -$14.2M |
| FY 2024 | $0 | $0 | — | — | -$733.5K | -$18.9M |
| FY 2023 | $0 | $0 | — | — | -$627.8K | -$19.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APUS // BETA —
IMNN // BETA —